Round Versus Teardrop Breast Implants: What Shape and Profile Actually Mean, Why Anatomical Implants Nearly Vanished From American Operating Rooms After 2019, and Why Blinded Surgeons Cannot Tell the Two Apart

Breast implants come in two shapes and, within each shape, a ladder of profiles, and the consultation usually spends more time on those two words than on anything except volume. Round or teardrop. Low, moderate, moderate plus, high, extra high. The words sound like a menu of looks, and the sales material treats them that way: the teardrop for the "natural" patient, the high profile for the patient who wants more. Neither description survives contact with how the devices actually behave once they are under tissue on a person who stands up, and the gap between what the catalog says and what the chest does is the subject of this piece.

The short version, which the rest of this article defends: shape is a smaller decision than the marketing suggests and profile is a larger one than patients realise, and both are decided mostly by measurements of the chest rather than by preference. The round implant has become the default in the United States for reasons that have as much to do with a recall in July 2019 as with aesthetics. The anatomical implant, once a third or more of the market in much of Europe, is now a niche device in American practice with a specific and defensible list of indications. And profile, which sounds like a style, is a geometric consequence of matching an implant's width to the width of the breast and then choosing how far forward it should stand.

This piece sits alongside the piece on how surgeons decide implant size, which covers volume and tissue-based planning and is not repeated here, the saline versus silicone piece, and the piece on the shift to pre-pectoral placement. Shape and profile are the two questions left over once fill, plane, and volume have been settled, and they are the two the industry has done the least to explain.

What round and anatomical implants actually are, and why one of them needs a rough shell

The short answer: a round implant is symmetrical in every direction and can be smooth; an anatomical implant is fuller at the bottom than at the top, has to stay oriented, and so almost always carries a textured shell that grips tissue to stop it turning.

A round implant is a dome. Its width and height are equal, its point of maximum projection sits at the centre, and it looks the same from any angle when you turn it on the table. Because it has no orientation it cannot be the wrong way up, and because it cannot be the wrong way up it can be made with a smooth shell that does not need to adhere to anything. Most round implants in current use are filled with a silicone gel soft enough to move: the gel settles toward the lower part of the implant when the patient stands and evens back into a dome when she lies flat. That behaviour is the origin of the claim, made by nearly every surgeon who favours round devices, that a round implant is a teardrop when the patient is upright.

An anatomical implant, also called shaped, teardrop, or form-stable, is designed with less volume at the top and more at the bottom, with the point of maximum projection sitting below the centre, and it is filled with a highly cohesive gel firm enough to hold that shape whether the patient is standing, lying, or upside down. The gel in these devices is the origin of the phrase "gummy bear," a marketing term that describes the way a cut section holds its form rather than any measurable standard, and the piece on trademarked procedure names covers why that kind of label deserves suspicion. Anatomical implants also come in a matrix rather than a single line: height and width are chosen separately, and the same width can be ordered in low, moderate, or full height with several projections for each, which is why the shaped catalogs run to dozens of combinations where the round catalogs run to a handful.

The cost of having a top and a bottom is that the implant can rotate. A round implant that turns in its pocket changes nothing. A shaped implant that turns 30 or 90 degrees puts its full lower pole to the side or the top, and the breast visibly changes shape. To prevent that, shaped implants are built with a textured surface intended to encourage the surrounding capsule to adhere to the shell and hold the device in position, and the surgeon has to dissect a pocket that fits the implant closely enough that it cannot move in the first place. Published series put the rate of clinically significant rotation somewhere between roughly one and five percent, which is low but not zero, and every case of it is a revision.

The textures are not all the same. The international standard for breast implants, ISO 14607, sorts shells into smooth, micro-textured, and macro-textured by average surface roughness, with the boundaries at roughly 10 and 50 microns. The coarser macro-textures produced the strongest tissue adhesion, the most reliable hold against rotation, and, as the field learned at some cost, the highest rate of the rare lymphoma that the BIA-ALCL piece covers in detail. That association is the hinge on which the whole shaped-implant story turned.

• Round: symmetrical, no orientation, can be smooth-shelled, softer gel, fuller upper pole, the large majority of the American market.
• Anatomical: fuller lower pole, must stay oriented, textured shell for adhesion, firmer form-stable gel, sold in a height-by-width-by-projection matrix, a small share of American cosmetic cases and a larger share of reconstruction.
• Rotation: the shaped implant's specific complication, reported in the low single digits of cases, always a revision.

Why shaped implants nearly disappeared from American practice after July 2019

The short answer: the FDA requested the recall of Allergan's Biocell macro-textured implants on July 24, 2019, the textured shell that most shaped implants depend on became a liability overnight, and the American market moved almost entirely to smooth round devices in the months that followed.

The United States was never a shaped-implant country. Through the 2010s, textured implants of both shapes were somewhere around a tenth to a fifth of American augmentations by most industry estimates, against a majority in much of Europe, Australia, and Latin America, where anatomical devices had been available for years before the FDA approved the first form-stable shaped implants in 2012 and 2013. American surgeons had grown up on smooth round saline and then smooth round gel, and the pitch for the shaped implant was always an uphill one against a device that was cheaper, softer, and could not rotate.

Then the lymphoma data matured. Breast implant-associated anaplastic large cell lymphoma had been on the FDA's radar since 2011, and by 2019 the agency's case counts made it clear that the disease clustered overwhelmingly around textured shells, with the Biocell macro-texture accounting for the large majority of cases in which the shell type was known. On July 24, 2019, the FDA asked Allergan to recall its Biocell textured implants and tissue expanders worldwide, and Allergan announced the recall the same day. Because the Natrelle 410 anatomical implant used the Biocell surface, the recall removed the largest shaped-implant line in the American market at a stroke. The FDA did not ask patients with those implants in place to have them removed absent symptoms, a position it has restated since, but no surgeon was going to put a recalled shell into a new patient.

What remained in the American shaped-implant drawer was small: Mentor's shaped implants on its finer Siltex micro-texture, and Sientra's textured shaped devices. The lymphoma association was weaker for those surfaces, but it was not nil, and the shaped-implant conversation now had to begin with a disclosure that the smooth round conversation did not need. Surgeons who had used shaped implants for a minority of cases largely stopped. Industry and society estimates in the years since have put textured implants of any shape at a low single-digit share of American augmentations, and the shaped implant went from a specialist's preference to a specialist's exception.

Two later developments closed the loop. In 2021 the FDA finalized a boxed warning and a patient decision checklist for all breast implants, which every patient now signs and which spells out the lymphoma risk and its association with texturing in plain terms; it is worth reading before the consultation rather than at it, and the long-term implant surveillance piece covers what follows the signature. And in September 2024 the FDA approved Motiva's round implants, made by Establishment Labs, adding a fourth manufacturer to Allergan, Mentor, and Sientra with a shell the company classes as smooth under the ISO roughness definition. The direction of that approval says something: the new entrant came in round and smooth, because that is where the American market now lives.

The FDA MAUDE database piece explains how to read the adverse event reports that drove the recall, and why raw counts from that database are easy to misread in either direction.

What the blinded studies found when surgeons tried to tell the two apart

The short answer: when plastic surgeons were shown photographs of the same patient with a round and a shaped implant placed in sequence during surgery, they identified the shape correctly at about the rate of a coin toss, and expressed no consistent preference for the teardrop.

The strongest piece of evidence on shape was published in Plastic and Reconstructive Surgery in 2017 by David Hidalgo and Andrew Weinstein, and its design is the reason it is worth trusting. In 75 consecutive augmentation patients, the surgeon placed a round implant and a shaped implant of comparable dimensions into the same pocket, one after the other, during the same operation, photographed each, and then closed with whichever the plan called for. The paired photographs went to a blinded panel of plastic surgeons, who were asked to say which breast held the shaped implant and which result they preferred. They picked the shaped implant correctly about half the time. Their preference, where they had one, leaned toward the round result. The patient's own tissue, the pocket, and the plane had done more to determine the final shape than the shape of the device.

That finding did not surprise the surgeons who had been arguing for round implants since the 1990s, and it had been foreshadowed by smaller blinded comparisons in the years before. It also did not settle the question, because the study's population was ordinary augmentation patients with reasonable tissue, and the claim for shaped implants was never that they looked different in the average case. It was that they looked different in the difficult one: the patient with almost no breast tissue and a thin upper chest, where a round dome of gel can produce a visible convexity at the top of the breast that reads as an implant from across a room. In that patient the shaped implant's tapered upper pole is doing real work, and no lineup of average cases refutes it.

"

The shape on the catalog page is the shape of the implant on a table. The only shape that matters is the one it takes under a standing patient's own tissue, and on that test the round and the teardrop are hard to tell apart.

"

Two other things the blinded literature makes clear. First, the upper pole fullness that shaped implants are designed to avoid is, for a large share of augmentation patients, the point of the operation. A patient who wants a fuller top to her breast, in a bra or a swimsuit, is asking for exactly the feature the teardrop is engineered against, and the "natural" label attached to shaped devices in marketing copy assumes a preference she may not hold; the piece on the word natural in plastic surgery marketing is about that assumption. Second, the round implant's tendency to settle into a teardrop when upright is real for softer gels and much less true of the firmer form-stable rounds now sold by every manufacturer, so a patient choosing a round implant is also, without always being told, choosing how round it will stay when she stands up.

• Hidalgo and Weinstein, 2017: 75 patients, round and shaped implants placed sequentially in the same pocket, blinded surgeon panel, correct identification near chance, preference leaning round.
• Where shape still shows: very thin upper pole tissue, minimal native breast, and the constricted or tuberous breast.
• Where it does not: the ordinary augmentation patient with a reasonable envelope, where pocket and plane decide the result.

What "profile" actually measures, and why it is a geometry decision rather than a look

The short answer: profile is the ratio of an implant's forward projection to its base width, and because the base width is set by the width of the patient's breast, choosing a profile is choosing how far forward a fixed-width implant should stand, which is a much narrower decision than the words low and high suggest.

Every implant has three published dimensions: width, projection, and volume. The FDA regulates breast implants as Class III devices with detailed labeling, and the manufacturers publish those numbers for every device in every line, which is what makes dimensional planning possible in the first place. The profile categories, which each company names slightly differently (low, moderate, moderate plus, high, extra high or ultra high, with brand-specific labels on top), are simply bands of the projection-to-width ratio. A low-profile implant is wide and shallow. A high-profile implant of the same width stands further forward and, because the extra projection is extra gel, holds more volume. On the order of magnitude, a 12 centimetre base width might correspond to something around 250 cubic centimetres in a low profile and past 400 in an extra-high one, with the moderate and moderate-plus bands in between.

That arithmetic is the point patients miss. The surgeon does not choose the profile and then find a size. The surgeon measures the breast base width, subtracts for the thickness of the tissue that will cover the implant at its edge, arrives at the maximum implant width the chest can take without the device spilling toward the armpit or the midline, and then moves up and down the profile ladder at that width to reach the volume the patient wants. Profile, in a properly planned augmentation, is the lever that converts a fixed width into a chosen volume. It is the reason two women asking for the same 350 cubic centimetres can be shown two devices of different widths and projections, and it is why "I want high profile" and "I want a moderate profile" are both requests the surgeon should translate rather than obey. The piece on tissue-based planning and implant size covers the measurement side of that in detail.

What the profile bands do change is the character of the result, and here the honest description is unflattering to both ends of the ladder. A high-profile implant at a given width delivers more forward projection with less lateral fullness: on a narrow chest with a reasonable envelope it can produce a proportionate result that a wider implant could not, and on a thin envelope it can produce the spherical, sharply defined upper edge that every patient says she does not want. A low or moderate profile at the same width spreads its volume across the chest: it produces a softer slope and less upper pole fullness, and, pushed too wide for the chest, it produces the lateral fullness that patients describe as their breasts sitting under their arms when they lie down. Neither is a look to be ordered. Each is a consequence to be predicted, and the 3D imaging piece explains how far the simulation can be trusted to predict it.

Cohesivity sits alongside profile as a second dial. Every current silicone implant is cohesive, meaning the gel holds together when cut, but the manufacturers grade firmness in steps, and a firmer gel resists rippling and holds projection better while feeling less like breast tissue to the hand. Firmer gels tend to be sold at the higher profiles and in the shaped devices. The patient who wants high projection, a soft feel, a thin envelope, and no rippling is asking for four things the physics will not deliver together, and the piece on the second consultation is the place to find out which of the four her surgeon has quietly dropped.

• Profile is projection divided by width. It is a ratio, not a style.
• Width is set by the chest. Profile then sets the volume available at that width.
• High profile: more projection, less lateral fullness, a more visible upper edge on thin tissue.
• Low and moderate profile: softer slope, more width, a risk of lateral spill if oversized.
• Firmer gel: less rippling and better-held shape, at the cost of a firmer feel.

Where each choice still makes sense: reconstruction, the tuberous breast, the empty upper pole, and the hand

The short answer: shaped implants retain a defensible place in reconstruction, in the constricted or tuberous breast, and in the very thin patient with no upper pole tissue; round implants suit almost everyone else; and the profile question is answered by the chest width and the patient's tolerance for a visible upper edge, not by a preference for a word.

The reconstruction case is the clearest. After mastectomy there is often no breast tissue at all to shape the result, the implant is the breast, and a device engineered with a sloped upper pole and a full lower pole does work that a round implant, sitting under nothing but skin and a thin layer of muscle or mesh, cannot. Shaped implants remained common in reconstruction after 2019 for exactly that reason, on the finer textures that survived the recall, and the piece on breast reconstruction after mastectomy describes the trade against the lymphoma disclosure that every reconstructive patient now signs. The same logic applies, with less force, to the cosmetic patient with almost no native breast and a thin upper chest: the tapered top of a shaped implant is a real advantage there, and the blinded studies, run on ordinary patients, do not contradict it.

The constricted breast is the second case. The tuberous or tubular breast, which the tuberous breast deformity piece covers, has a narrow base, a tight lower pole, and a herniated areola, and the operation is a matter of expanding the lower pole against its own resistance. Surgeons divide on whether a shaped implant or a round one does that better, and the answer often depends on the release performed on the tissue rather than on the device; but the shaped implant's built-in lower pole fullness is one of the few places its geometry addresses a problem the round implant does not.

Everywhere else, the round implant is the default for reasons that are not only about the recall. It is softer. It cannot rotate. It can be placed through a smaller incision. It carries a smooth shell with the lowest reported lymphoma association of any surface, and it produces the upper pole fullness that a large share of cosmetic patients came in wanting. A surgeon who reaches for a shaped implant in an ordinary augmentation should be able to name the specific feature of this patient's tissue that a round implant would fail on, and a surgeon who reaches for a round implant should be able to say how firm a gel the patient is getting and what it will do when she stands.

The hand matters more than the catalog concedes. Shaped implants and high-profile form-stable rounds are firmer, and a patient with thin tissue over a firm implant feels the device every time she lies on her side. Sizers, simulation, and gel samples all exist, and the imaging systems model volume reasonably well and feel not at all; the only way to know what a firmer gel is like is to hold one, and a consultation that does not put the gel in the patient's hand has skipped the one input the screen cannot supply. The piece on reading a before-and-after gallery explains why photographs, which capture shape and nothing else, are a poor guide to the rest.

Finally, none of this is permanent. Implants are exchanged, and the piece on whether implants need replacing covers when; capsules contract, and the capsular contracture piece covers how a contracted capsule distorts a shaped implant more visibly than a round one; and the patient who does not want a device in either shape has the option that the fat transfer to the breast piece describes, with its own limits on volume. The shape and profile chosen at 28 are the shape and profile revised at 42, and the surgeon who plans the first operation with the second in mind is the one worth paying.

The honest summary

• Shape is a smaller decision than the catalog implies. Blinded surgeons pick the teardrop out of a lineup at about the rate of chance, and most cosmetic patients want the upper pole fullness the shaped implant is designed to remove.
• The shaped implant nearly left American practice for a reason. The July 2019 recall of Biocell macro-textured shells took the largest shaped line off the market, and the textured surface a shaped implant needs to stay oriented now comes with a lymphoma disclosure the smooth round implant does not carry.
• Shaped implants still earn their place on a short list. Reconstruction, the tuberous or constricted breast, and the very thin upper pole are the cases where the tapered top does real work, and a surgeon proposing one should be able to say which of the three applies.
• Profile is geometry, not style. It is projection divided by width; width is set by the chest; profile is the lever that converts that width into a volume, and each band brings a predictable consequence at the upper edge and at the side.
• The hand is the missing input. Firmer gels ripple less, hold shape better, and feel less like breast; only a sample in the hand tells the patient which trade she is making.

The patient who does well with implants is usually the one who walked in with a volume in mind and let the surgeon's tape measure turn it into a width, a profile, and a shape, in that order. The patient who ends up in a revision is often the one who walked in with a word, teardrop or high profile or natural, found a surgeon willing to sell her the word, and discovered a year later that the word described a device on a table rather than a breast on a body. The catalog is not the decision. The chest is, and the three questions above are how to find out whether the surgeon has read it.